Literature DB >> 18392862

Impact of skeletal complications on patients' quality of life, mobility, and functional independence.

Luis Costa1, Xavier Badia, Edward Chow, Allan Lipton, Andrew Wardley.   

Abstract

INTRODUCTION: Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life. DISCUSSION: Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18392862     DOI: 10.1007/s00520-008-0418-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.359


  68 in total

1.  Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.

Authors:  Norio Kohno; Kenjiro Aogi; Hironobu Minami; Seigo Nakamura; Taro Asaga; Yuichi Iino; Toru Watanabe; Carsten Goessl; Yasuo Ohashi; Shigemitsu Takashima
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

2.  Changes in quality of life during palliative chemotherapy for solid cancer.

Authors:  Soo-Mee Bang; Se Hoon Park; Hee Geun Kang; Jung In Jue; In Hee Cho; Young Ho Yun; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Support Care Cancer       Date:  2005-01-28       Impact factor: 3.603

3.  The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.

Authors:  A Heidenreich; R Hofmann; U H Engelmann
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

Review 4.  Burden of bone disease.

Authors:  Nicole Kinnane
Journal:  Eur J Oncol Nurs       Date:  2007-09-04       Impact factor: 2.398

5.  A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.

Authors:  Mark Clemons; George Dranitsaris; Wei Ooi; David E C Cole
Journal:  Breast Cancer Res Treat       Date:  2007-05-02       Impact factor: 4.872

6.  Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.

Authors:  N O'Rourke; E McCloskey; F Houghton; H Huss; J A Kanis
Journal:  J Clin Oncol       Date:  1995-04       Impact factor: 44.544

Review 7.  The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials.

Authors:  F Fulfaro; A Casuccio; C Ticozzi; C Ripamonti
Journal:  Pain       Date:  1998-12       Impact factor: 6.961

8.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

9.  Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.

Authors:  Jean-Jacques Body; Ingo J Diel; Richard Bell; Martin Pecherstorfer; Michail R Lichinitser; Alexander F Lazarev; Debu Tripathy; Bengt Bergström
Journal:  Pain       Date:  2004-10       Impact factor: 6.961

10.  Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.

Authors:  A Wardley; N Davidson; P Barrett-Lee; A Hong; J Mansi; D Dodwell; R Murphy; T Mason; D Cameron
Journal:  Br J Cancer       Date:  2005-05-23       Impact factor: 7.640

View more
  71 in total

Review 1.  Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?

Authors:  Simon P Gampenrieder; Gabriel Rinnerthaler; Richard Greil
Journal:  Breast Care (Basel)       Date:  2014-10       Impact factor: 2.860

2.  Percutaneous balloon kyphoplasty of malignant lesions of the spine: a prospective consecutive study in 115 patients.

Authors:  Max Markmiller
Journal:  Eur Spine J       Date:  2015-01-08       Impact factor: 3.134

3.  Safety and efficacy of multilevel vertebroplasty for painful osteolytic spinal metastases: a single-centre experience.

Authors:  Jian-Jun Zhang; Yan Zhou; Hai-Yan Hu; Yuan-Jue Sun; Yong-Gang Wang; Yi-Feng Gu; Chun-Gen Wu; Zan Shen; Yang Yao
Journal:  Eur Radiol       Date:  2016-12-14       Impact factor: 5.315

Review 4.  A Focused Review of Safety Considerations in Cancer Rehabilitation.

Authors:  Susan Maltser; Adrian Cristian; Julie K Silver; G Stephen Morris; Nicole L Stout
Journal:  PM R       Date:  2017-09       Impact factor: 2.298

5.  Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.

Authors:  Jianqing Lin; Victoria J Sinibaldi; Michael A Carducci; Samuel Denmeade; Danny Song; Theodore Deweese; Mario A Eisenberger
Journal:  Urol Oncol       Date:  2009-12-04       Impact factor: 3.498

6.  Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.

Authors:  Alysia N Lozano-Ondoua; Katherine E Hanlon; Ashley M Symons-Liguori; Tally M Largent-Milnes; Josh J Havelin; Henry L Ferland; Anupama Chandramouli; Mabel Owusu-Ankomah; Tijana Nikolich-Zugich; Aaron P Bloom; Juan Miguel Jimenez-Andrade; Tamara King; Frank Porreca; Mark A Nelson; Patrick W Mantyh; Todd W Vanderah
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

7.  Breast cancer and bone metastases: a call for appropriate treatment.

Authors:  Diana Lüftner; Daniela Niepel
Journal:  Support Care Cancer       Date:  2016-07-25       Impact factor: 3.603

8.  Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis.

Authors:  Akanksha Srivastava; Graciela M Nogueras Gonzalez; Yimin Geng; Alexander M Won; Maria E Cabanillas; Aung Naing; Jeffrey N Myers; Yisheng Li; Mark S Chambers
Journal:  Support Care Cancer       Date:  2020-11-15       Impact factor: 3.603

9.  Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.

Authors:  Laura Murphy; Joy McCarthy; Farah McCrate; Kara Laing; Erin Powell; Melanie Seal; Scott Edwards
Journal:  Support Care Cancer       Date:  2013-01-19       Impact factor: 3.603

10.  Balloon kyphoplasty in malignant spinal fractures: a systematic review and meta-analysis.

Authors:  Carmen Bouza; Teresa López-Cuadrado; Patricia Cediel; Zuleika Saz-Parkinson; José María Amate
Journal:  BMC Palliat Care       Date:  2009-09-09       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.